Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts. Show more

Location: 490 Arsenal Way, Watertown, MA, 02472, United States | Website: https://tectonictx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

285.2M

52 Wk Range

$13.70 - $61.07

Previous Close

$15.25

Open

$15.39

Volume

378,140

Day Range

$14.96 - $15.46

Enterprise Value

-78.05K

Cash

287.4M

Avg Qtr Burn

-16.06M

Insider Ownership

38.39%

Institutional Own.

65.07%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.